Lumida
/TEVA
⌘K
Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd

TEVA
$37.56USD+0.20%+0.07 today

MARKET CAP

42.4B

P/E (TTM)

31.3x

FWD P/E

DAY RANGE

$37 – $38

52W RANGE

$18
$38

AI Summary

Stalk
Buy NowMedium

TEVA remains in a Stage 2 advancing context with a clear Higher Highs & Higher Lows uptrend, now digesting gains just below its 52-week high while holding rising 9- and 20-day EMAs. This pullback into dynamic support, against the backdrop of healthy momentum and neutral RSI, offers a favorable entry to participate in a breakout continuation. We will execute now to capture further upside potential ahead of a potential breach above the recent high.

  • Esteto sales +43% YoY; pipeline on track for $3.7B revenue by 2026
  • Net debt reduced to $12.9B; net debt/EBITDA at 2.8x versus 2.0x target
  • Generics segment revenue fell 15% YoY on generic Revlimid swings
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$15.9B$14.9B$15.8B$16.5B$17.3B
YoY %-4.7%-6.0%+6.2%+4.4%+4.3%
P / Sales0.6x0.7x0.8x1.5x2.1x
EV / Sales2.7x2.9x2.8x3.3x3.8x
Gross Profit, Adj.$7.6B$7.0B$7.6B$8.1B$8.9B
YoY %-1.7%-8.2%+9.7%+5.5%+10.9%
Margin %47.8%46.7%48.3%48.7%51.8%
EV / Gross Profit5.7x6.2x5.8x6.9x7.3x
EBITDA, Adj.$3.8B$2.0B$4.4B$4.4B$4.9B
YoY %-18.1%-46.9%+117.4%+0.9%+11.2%
Margin %24.0%13.6%27.7%26.8%28.6%
EV / EBITDA11.3x21.4x10.0x12.5x13.3x
EBIT$1.7B$-2.2B$433.0M$-303.0M$2.2B
YoY %+148.1%-228.0%+119.7%-170.0%+811.9%
Margin %10.8%-14.7%2.7%-1.8%12.5%
EV / EBIT25.1x-19.7x101.8x-182.3x30.4x
Net Income$417.0M$-2.4B$-559.0M$-1.6B$1.4B
YoY %+110.5%-686.6%+77.1%-193.2%+186.0%
Net Margin2.6%-16.4%-3.5%-9.9%8.2%
EPS (GAAP)$0.38-$2.20-$0.50-$1.45$1.21
YoY %+110.4%-678.9%+77.3%-190.0%+183.4%